- Home
- XNCR vs SAVA Comparison
XNCR vs SAVA Comparison
Compare XNCR & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- SAVA
- Stock Information
- Founded
- XNCR 1997
- SAVA 1998
- Country
- XNCR United States
- SAVA United States
- Employees
- XNCR N/A
- SAVA N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- SAVA Health Care
- Exchange
- XNCR Nasdaq
- SAVA Nasdaq
- Market Cap
- XNCR 1.5B
- SAVA 1.3B
- IPO Year
- XNCR 2013
- SAVA N/A
- Fundamental
- Price
- XNCR $24.10
- SAVA $32.18
- Analyst Decision
- XNCR Strong Buy
- SAVA Strong Buy
- Analyst Count
- XNCR 8
- SAVA 3
- Target Price
- XNCR $35.50
- SAVA $111.50
- AVG Volume (30 Days)
- XNCR 569.4K
- SAVA 1.6M
- Earning Date
- XNCR 11-06-2024
- SAVA 11-07-2024
- Dividend Yield
- XNCR N/A
- SAVA N/A
- EPS Growth
- XNCR N/A
- SAVA N/A
- EPS
- XNCR N/A
- SAVA N/A
- Revenue
- XNCR $85,164,000.00
- SAVA N/A
- Revenue This Year
- XNCR N/A
- SAVA N/A
- Revenue Next Year
- XNCR $86.53
- SAVA N/A
- P/E Ratio
- XNCR N/A
- SAVA N/A
- Revenue Growth
- XNCR N/A
- SAVA N/A
- 52 Week Low
- XNCR $15.31
- SAVA $8.79
- 52 Week High
- XNCR $26.84
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- XNCR 70.71
- SAVA 64.80
- Support Level
- XNCR $22.60
- SAVA $25.72
- Resistance Level
- XNCR $23.86
- SAVA $29.49
- Average True Range (ATR)
- XNCR 0.83
- SAVA 2.63
- MACD
- XNCR 0.05
- SAVA 0.48
- Stochastic Oscillator
- XNCR 96.85
- SAVA 82.89
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.